GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » ROE % Adjusted to Book Value

MYND Life Sciences (XCNQ:MYND) ROE % Adjusted to Book Value : 0.00% (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences ROE % Adjusted to Book Value?

MYND Life Sciences's ROE % for the quarter that ended in Jul. 2024 was 0.00%. MYND Life Sciences's PB Ratio for the quarter that ended in Jul. 2024 was N/A. MYND Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Jul. 2024 was N/A.

MYND Life Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for MYND Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences ROE % Adjusted to Book Value Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
ROE % Adjusted to Book Value
- - -

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Equity - - -

Competitive Comparison of MYND Life Sciences's ROE % Adjusted to Book Value

For the Biotechnology subindustry, MYND Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MYND Life Sciences's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's ROE % Adjusted to Book Value falls into.


;
;

MYND Life Sciences ROE % Adjusted to Book Value Calculation

MYND Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Oct. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

MYND Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Jul. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MYND Life Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
XCNQ:MOOD XCNQ:HEAL XCNQ:ENBI XCNQ:CHGX XCNQ:MBIO XCNQ:NIRV XCNQ:NSHS XCNQ:AGN TSXV:WAVE XCNQ:WBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MYNDF:USA
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
Website
https://www.myndsciences.com
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.